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Abstract
We used mandrills (Mandrillus sphinx) naturally infected with simian T-cell leukemia virus type 1 (STLV-1) as a model for
evaluating the influence of natural STLV-1 infection on the dynamics and evolution of the immune system during chronic
infection. Furthermore, in order to evaluate the role of the immune system in controlling the infection during latency, we
induced immunosuppression in the infected monkeys. We first showed that the STLV-1 proviral load was higher in males
than in females and increased significantly with the duration of infection: mandrills infected for 10–6 years had a
significantly higher proviral load than those infected for 2–4 years. Curiously, this observation was associated with a clear
reduction in CD4+ T-cell number with age. We also found that the percentage of CD4
+ T cells co-expressing the activation
marker HLA-DR and the mean percentage of CD25
+ in CD4
+ and CD8
+ T cells were significantly higher in infected than in
uninfected animals. Furthermore, the STLV-1 proviral load correlated positively with T-cell activation but not with the
frequency of T cells secreting interferon c in response to Tax peptides. Lastly, we showed that, during immunosuppression
in infected monkeys, the percentages of CD8
+ T cells expressing HLA-DR
+ and of CD4
+ T cells expressing the proliferation
marker Ki67 decreased significantly, although the percentage of CD8
+ T cells expressing HLA-DR
+ and Ki67 increased
significantly by the end of treatment. Interestingly, the proviral load increased significantly after immunosuppression in the
monkey with the highest load. Our study demonstrates that mandrills naturally infected with STLV-1 could be a suitable
model for studying the relations between host and virus. Further studies are needed to determine whether the different
compartments of the immune response during infection induce the long latency by controlling viral replication over time.
Such studies would provide important information for the development of immune-based therapeutic strategies.
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agent of adult T-cell leukemia/lymphoma (ATLL) [1] and of
tropical spastic paraparesis/HTLV-1-associated myelopathy (TSP/
HAM) [2], has also been implicated in pediatric infectious
dermatitis [3], uveitis [4], arthropathy [5] and polymyositis [6].
Simian T cell leukemia virus (STLV–1), the simian counterpart
of HTLV-1, naturally infects Old World monkeys and shares
virologic, immunologic, molecular, and pathologic features with
HTLV-1 [7–9]. The phylogenic relations of most known subtypes
indicate that STLV-1 is the simian ancestor of HTLV-1, the latter
arising by transmission from multiple nonhuman primates to
humans [10–14]. In naturally infected monkeys, STLV-1 causes
diseases similar to those induced by HTLV-1 in humans, ATLL-
like pathological features occurring in a minority of individuals
after a long latency [15–18].
In Africa, STLV-1 infection has been detected in both species of
great ape (Pan and Gorilla) as well as in the Old World monkey family
Cercopithecidae [9]. The mandrill (Mandrillus sphinx), with a
geographic distribution restricted to the tropical forests of Cameroon,
Equatorial Guinea, Gabon, and southern Congo [11,19], is subject to
infection with an STLV-1 subtype closely related to HTLV-1. The
first cases of natural STLV infection in mandrills (STLVmnd) were
detected during a retrospective serological survey at the Primate
Centre of the International Centre for Medical Research (CIRMF) in
Gabon. Two males were STLV-1-seropositive on their arrival at
CIRMF, strongly supporting the existence of STLV infection in the
wild. Natural transmission of the virus has been monitored since the
breeding colony was created in 1983 [20]. The first genetic studies of
STLVmnd indicated the presence of two genetically distinct strains
[19], intracolony transmission occurring mainly through male–male
aggression [20,21]. It has also been reported that STLV from
mandrills is closely related to HTLV-1. The possibility of cross-
species transmission of STLV-1 to humans is supported by the fact
that the STLVmnd viruses so far characterized are genetically similar
to HTLV-1 subtype D and F viruses isolated from people living in
central Africa [11,19]. Moreover, African HTLV-1 and STLV-1
cannot be separated into distinct phylogenetic lineages on the basis of
their species of origin, but rather on the geographic origin of their
PLoS ONE | www.plosone.org 1 June 2009 | Volume 4 | Issue 6 | e6050hosts. All this suggests that STLV infection of mandrills could serve as
a model of human HTLV infection. Although the phylogenetics of
STLV-1 infection of mandrills are well documented, few data are
available on the virologic or molecular determinants of natural
STLV-1 infection in this host species. Moreover, little is known about
the initial and latent phases of STLV-1/HTLV-1 infection in terms
of proviral load, reservoir cells, viral expression, the pattern of viral
integration (clonality), the initial target cells, and the role of cytotoxic
T-cell responses during natural infection in nonhuman primates. We
therefore examined immunological and virological patterns in a large
group of naturally STLV-1-infected mandrills, including T-cell
subsets, proviral load, and STLV-specific T-cell responses. Further-
more, to evaluate the role of the immune system in controlling
STLV-1 infection, we induced immunosuppression in naturally
infected mandrills and evaluated the dynamics of immunologic and
virologic parameters during and after treatment.
Results
High STLV-1 prevalence and high proviral load in
naturally infected mandrills
Sera from 142 mandrills (58 males, 84 females; mean age, 10.7
years) were tested by ELISA for the presence of anti-STLV-1
antibodies. Positive samples were confirmed by western blotting.
As shown in Table 1, 19 mandrills (13.4%), all with complete
western blot profiles, had antibodies against HTLV-1. The
prevalence of STLV-1 infection increased significantly with age
(p=0.001), from 0% at 1–4 years to 12.9% at 5–10 years, 18.1%
at 11–15 years, and 33.3% at .16 years. More males than females
were infected (17.2% vs 10.7%). No mandrills under 4 years of age
were infected. The prevalence remained stable with age in females
but increased with age in males, reaching 87.5% at .16 years.
STLV-1 proviral load was determined by real-time PCR for 19
infected mandrills (11 males and 8 females). On average, 4.56% of
peripheral blood mononuclear cells (PBMC) were infected (range,
0.54–12.7%); however, the mean proviral load was higher in males
(5.11%) than in females (3.81%) (Figure 1A) and increased with
age (Figure 1B). Furthermore, the proviral load increased
significantly with the duration of infection (Figure 1C): mandrills
infected for 8–15 years had significantly higher proviral loads than
those infected for 2–4 years (mean, 8.464.8 versus 3.262.9).
Evaluation of T-cell subsets and influence of STLV-1
infection on T-cell response
In order to evaluate the role of STLV-1 infection in the
evolution of the cellular immune response, the distribution of T-
cell subsets defined by the markers CD4, CD8, HLA-DR, and
CD25 were compared in 17 STLV-1-infected (two infected
mandrills died of old age) and 59 uninfected animals. As shown
in Figure 2A and 2D, the percentages of CD4
+ and CD8
+ T cells
were similar. In contrast, the percentage of CD4
+ T cells co-
expressing the activation marker HLA-DR was significantly higher
in infected than in uninfected animals (p=0.001) (Figure 2B), even
though no change was noted in the percentage of HLA-DR
markers in CD8




+ T cells (24.0% and
11.7%, respectively) were higher in infected than in uninfected
animals (20.8% and 9.6%, respectively); this difference was not
statistically significant (Figure 2C and 2F).
The percentages of T-cell subsets were then correlated with the
proviral load. As seen in Figure 3, the percentage of CD4+ T cells
correlated negatively with the STLV-1 proviral load, while the
percentage of CD8
+ T cells showed a positive correlation
(Figure 3A and 3D). A positive correlation was also found between





+ T cells and CD8
+ T cells (Figure 3B, C,
and F). No correlation was found between the STLV-1 proviral
load and the percentage of CD8
+ cells expressing the activation
marker HLA-DR
+ (Figure 3E).
STLV-1-specific cellular immune responses in chronically
infected mandrills
The frequency of T cells secreting interferon (IFN)-c in response
to 82 overlapping peptides covering the totality of the Tax gene
(Table 2) was evaluated by ELISPOT in the six chronically STLV-
1-infected mandrills and in one uninfected monkey. As shown in
Figure 4, T cells from all six mandrills secreted IFN-c in the
presence of at least one pool of peptides. All the peptide pools were
able to induce IFN-c secretion in the STLV-1-infected monkeys
but not in the uninfected control, and none was found to be more
immunogenic than the others. No correlation was found between
STLV proviral load and the frequency of STLV-specific cellular
immune responses (data not shown). It is noteworthy, however,
that the strongest cellular immune response was found in an
animal (#MND 5) with a low proviral load (1.3%). Therefore, to
evaluate the role of the cellular immune response in controlling
STLV-1, we investigated the effect of immunosuppressive
treatment on the dynamics of the STLV proviral load and on
the distribution of T-cell subsets.
Effect of immunosuppressive treatment in mandrills
chronically infected with STLV-1
Two groups of three mandrills were selected on the basis of their
proviral burden, with low, medium and high burdens in each
group. The first group was immunosuppressed with tacrolimus,
whereas the second group received phosphate-buffered saline as a
control. Both the proviral load and the CD4, CD8, HLA-DR, and
Ki67 T cell populations were evaluated before (week –2, week –1,
and day 0), during (weeks +1, +2, and +3) and after treatment
(weeks +4, +5, +6, +7, and +8).
No effect on the biochemical markers usually seen during
immunosuppression in humans was found (data not shown). One
week after immunosuppression, tacrolimus was detected in the
blood of treated monkeys within the therapeutic range used in
humans (Figure 5A).
Proviral load was expressed as the mean value for each animal
before, during, and after therapy. As seen in Figure 5B and 5C,
there was no significant variation in the proviral load in control or
treated mandrills with low or medium proviral loads, but the
proviral load increased significantly in the mandrill with the
Table 1. Distribution of STLV-1 infection in our semi-free-
ranging colony of 142 mandrills by age group and sex.




tested % Total %
1–4 0/16 0 0/21 0 0/37 0
5–10 2/30 6.6 6/32 18.8 8/62 12.9
11–15 1/4 25 3/18 16.7 4/22 18.1
.16 7/8 87.5 0/13 0 7/21 33.3
Total 10/58 17.2 9/84 10.7 19/142 13.4
doi:10.1371/journal.pone.0006050.t001
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(Figure 5B).
The mean numbers of T-cell subsets were measured in all
animals in each group before, during, and after tacrolimus
treatment. Tacrolimus did not affect the percentages of CD4
+ or
CD8
+ T cells (Figure 6A and 6B) or the disruption of naive and
memory T cells (data not shown). In contrast, the percentage
CD8
+ expression of HLA-DR+ decreased significantly during
therapy (p=0.01) (Figure 6D), whereas the percentage of CD4+ T
cells expressing the proliferation marker Ki67 decreased signifi-
cantly during treatment (p=0.01) but increased significantly after
the end of treatment (p,0.001), as did the percentage of CD8
+ T
cells expressing Ki67 (p,0.001) (Figure 6E and 6F). The control
groups showed no statistically significant change in the percentages
of CD4
+ and CD8
+ cells expressing HLA-DR during or after
treatment (Figure 6C and 6D).
Discussion
Our study provides the first in-depth virological and immuno-
logical characterization of natural STLV-1 infection in a
nonhuman primate. We further evaluated the influence of this
natural infection on the dynamics and evolution of the immune
system during chronic infection and after the induction of
immunosuppression in the infected monkeys.
When the mandrill colony was created in 1983, only two
founder males were infected with STLV-1. Phylogenetic studies
have since shown that they were infected with subtypes D and F
[19]. A retrospective study of the same colony showed that in 1995
eight males were STLV-1-seropositive. The suspected mode of
transmission was through bites inflicted during fights for
dominance [21]. No females were infected at that time. The data
reported here show that the prevalence is now high in males and
increases markedly with age. We also show that females are now
infected, but at a lower prevalence than in males, even among the
oldest females. Transmission during fights cannot be ruled out, but
sexual transmission, as in humans, should be considered. No cases
of infection were detected among juveniles (,4 years), ruling out
transmission in utero or during breastfeeding. Thus, the modes of
STLV-1 transmission appear to be slightly different from those in
humans, where the major mode of transmission is sexual or from
mother to child during breastfeeding. It was reported previously
that the rate of HTLV-1 transmission in humans, particularly
from infected mothers to infants, increases significantly when
women have a high HTLV-1 proviral load [22,23]. Thus, even if
the route of STLV-1 transmission in mandrills is different, the high
Figure 1. STLV-1 proviral load as detected by real-time PCR in 19 mandrills, expressed as copy numbers of provirus per 100 PBMC.
(A) Proviral load distribution in male and female monkeys. (B) Correlation of STLV-1 proviral load with age of monkeys. (C) Correlation of STLV-1
proviral load with duration of STLV-1 infection.
doi:10.1371/journal.pone.0006050.g001
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rate of STLV-1 transmission in the colony. A recent study in a
baboon colony showed that females were more frequently infected
than males [24]. These results illustrate that different patterns of
behavior of different nonhuman primates result in different
profiles of virus circulation.
We also showed a wide range of STLV-1 proviral loads in
PBMCs of infected monkeys. In some mandrills, the proviral load
was very high (up to 12.7% of PBMCs), reaching levels usually
associated with the onset of clinical manifestations in HTLV-1-
infected humans, whereas the mandrills naturally infected with
STLV-1 appeared healthy. Few reports have been made of the
STLV proviral load in naturally infected monkeys [25]. Those
authors reported a high STLV-1 proviral load in naturally infected
Celebes macaques (Macaca tonkeana) without inflammatory disease.
Nevertheless, HTLV-1-associated disease is rare in humans, with
less than 5% infections after a long incubation period [26]. In
order to demonstrate that STLV-1 can also induce inflammatory
disease in its natural host, however, a long-term clinical survey of
infected monkeys will be necessary.
Our study shows that proviral load iscorrelated positively with the
duration of infection and thuswith theage of theanimals. Nofollow-
up study of STLV-1-infected monkeys has previously been reported.
In some studies in humans, however, there was no clear evidence of
an association between proviral load and duration of infection [27].
It has been shown that the HTLV-1 proviral load is a strong
predictor of disease progression, and patients with TSP/HAM or
adult T-cell leukemiahave a higher proviral load thanasymptomatic
HTLV-1 carriers [28,29]. Furthermore, people infected with
HTLV-1 develop associated diseases such as ATLL after long
latency periods (30–40 years). It has been suggested previously that
the development of associated disease in older individuals could be
related to an immunosenescence phenomenon that leads to
expansion and activation of HTLV-1-infected cells [30]. In order
to clarify the relation between the increased level of STLV-1 in older
monkeys and the role of the immune response during life, we
evaluated the numbers of CD4
+ and CD8
+ T cells in STLV-1-
infected and uninfectedmonkeysofdifferent ages and observed clear
reductions in the absolute numbers of both CD4
+ and CD8
+ Tc e l l s
in older than in younger monkeys (Figure S1). Thus, the equilibrium
between viral replication and the destruction and activation of CD4
+
and CD8
+ T cells might define the course of STLV-1 infection
duringthelonglatency.ThelossofCD4
+Tcellscould induceastate
of immunodeficiency in older individuals. These findings are in
accordance with the observation that disequilibrium of the immune
system with age can lead to uncontrolled virus expansion and thus to
a high proviral load, which could lead further to disease progression.
Each STLV-1-infected monkey will have to be followed-up to
evaluate the dynamics of the STLV-1 proviral load and its
correlation with various modifications in the immune response that
could lead to disease progression afterthelonglatency. Thesestudies
are under way.
In the present study, we found that the percentage of CD4
+ T
cells co-expressing the activation marker HLA-DR
+ was higher in
STLV-1-infected monkeys than in uninfected control animals.
Furthermore, there was a significant correlation between activated
Figure 2. Comparisons of T-cell subsets in blood from 17 out of 19 mandrills infected with STLV (N) and 59 uninfected mandrills (%).
(A) Percentages of CD3
+CD4
+ cells. (B) Percentages of HLA-DR in CD4
+ T cells. (C) Percentages of CD25
+ in CD4
+ T cells. (D) Percentages of CD3
+CD8
+
cells. (E) Percentages of HLA-DR in CD8
+ T cells. (F) Percentages of CD25
+ in CD8
+ T cells. Statistical analyses for each T-cell subset in the two groups of
mandrills were performed with the Mann-Witney test. The only significant difference was in the percentage of HLADR in CD4
+ T cells (p=0.001).
doi:10.1371/journal.pone.0006050.g002
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+ cells and proviral load, and
primates with high proviral loads had elevated numbers of these
cells. In humans, HTLV-1 leukemic cells have an activated
helper/inducer T-cell phenotype, CD4
+CD25
+, which could be
activated by the HTLV-1 Tax oncogene [31,32,33]. We showed
recently that both CD4
+ and CD8
+ T cells are infected in STLV-1
infected mandrills [34]. Furthermore, a spontaneous T-cell
leukaemia/lymphoma has been described in some African
monkeys naturally infected with STLV-1 [16,17,35–38], in which
both CD4
+ [15,18] and CD8
+ [37,39] cells are involved. The
results presented in this paper thus reinforce the observation that
these cells might be involved in the development of associated
diseases.
Regulatory T (Treg) cells express CD4
+ and CD25
+ and have
potent immune response suppressive activity [40]; however, their
exact role in HTLV-1 infection is unknown. In recent studies,
leukaemia cells from patients with ATLL strongly expressed FoxP3
[32], a specific marker for Treg cells. These cells constitute about
2–3% of human CD4
+ T cells [40], and they have increasingly
been found to play conflicting roles in both autoimmune and
infectious disease. Yamano et al. [41] showed that HTLV-1 Tax
induced dysfunction of CD4
+CD25
+ T cells in patients with
HTLV-I-associated neuroimmunological disease. More recently,




the chief determinants of the efficiency of T-cell-mediated immune
control of HTLV-1. In our study, however, we observed no
pathologic or clinical manifestations of inflammatory status. Thus,
further physiopathologic characterization is required to define the
association between natural STLV-1 infection and associated
disease in this animal model. In humans, only 2–8% of HTLV-1-
infected persons develop a severe HTLV-1-associated disease like
ATLLL or TSP/HAM during their lifetime, generally after a long
latency [26]. Furthermore, in monkeys, associated diseases such as
ATLL have been related, in some cases, to co-infection with SIV
[17,43]. Mandrills are also naturally infected with simian
immunodeficiency virus (SIVmnd) [44]. As only monkeys infected
with STLV-1 were selected for the present study, co-infection with
SIV in our mandrill colony might account for the development of
associated diseases. Thus, long-term clinical studies in non-human
primates are required to evaluate the relation between STLV-1
infection and the development of associated diseases.
In order to elucidate the role of the immune system in
controlling STLV infection, we evaluated the frequency of
circulating effector T cells against Tax in chronically STLV-1-
infected monkeys. Although the response to the various peptides
was different in each monkey, a response was detected in all. In
our studies with chronically infected squirrel monkeys, we showed
the presence of a cytolytic T-cell response against Tax in enriched
CD8
+ T cells [45]. The present study reports for the first time a
cellular immune response against Tax, although we could not
identify the cells involved, and further studies are needed.
To determine whether the cellular immune response during
chronic STLV-1 infection in natural hosts controls STLV-1
replication over time, resulting in the long latency, immunosup-
pression studies with tacrolimus (FK506) were conducted. It has
been reported previously that some graft recipients treated with
immunosuppressive drugs develop ATLL [46–48]. In a study of
patients treated with various immunosuppressive drugs, those
given tacrolimus had a higher risk for ATL than those treated with
cyclosporin [49,50]. In our study, we observed no clinical
manifestation related to STLV-1 infection after immunosuppres-
sion, although some significant modifications were observed in the
Figure 3. Evolution of T-cell subsets in the 17 STLV-infected mandrills, correlated with their respective proviral load. (A) Percentages
of CD3
+CD4
+ cells. (B) Percentages of HLA-DR in CD4
+ T cells. (C) Percentages of CD25 in CD4
+ T cells. (D) Percentages of CD3
+CD8
+ cells. (E)
Percentages of HLA-DR in CD8
+ T cells. (F) Percentages of CD25 in CD8
+ T cells. Regression curves are shown as black lines.
doi:10.1371/journal.pone.0006050.g003
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from STLV-1-infected mandrills.
Pool Peptide No Sequences Pool Peptide No Sequences
Pool 1–5 1 LLFGYPVYVFGD Pool 41–45 41 HPGQLGAFLTNV
2 YPVYVFGDCVQG 42 LGAFLTNVPYKR
3 VFGDCVQGDWCP 43 LTNVPYKRMEEL
4 CVQGDWCPISGG 44 PYKRMEELLYKI
5 DWCPISGGLCSA 45 MEELLYKISLTT
Pool 6–10 6 ISGGLCSARLHR Pool 46–50 46 LYKISLTTGALI
7 LCSARLHRHALL 47 SLTTGALIILPE
8 RLHRHALLATCP 48 GALIILPEDCLP
9 HALLATCPEHQI 49 ILPEDCLPTTLF
10 ATCPEHQITWDP 50 DCLPTTLFQPAR
Pool 11–15 11 EHQITWDPIDGR Pool 51–55 51 TTLFQPARAPAT
12 TWDPIDGRVIGS 52 QPARAPATLTAW
13 IDGRVIGSALQF 53 APATLTAWQNGL
14 VIGSALQFLIPR 54 LTAWQNGLLPFH
15 ALQFLIPRLPSF 55 QNGLLPFHSTLT
Pool 16–20 16 LIPRLPSFPTQR Pool 56–60 56 LPFHSTLTTPGL
17 LPSFPTQRTSKT 57 STLTTPGLIWTF
18 PTQRTSKTLKVL 58 LIWTFTDGTPMI
19 TLKVLTPPTTHT 59 FTDGTPMISGPC
20 LTPPTTHTTPNI 60 TPMISGPCPKDG
Pool 21–25 21 TTHTTPNIPPSF Pool 61–65 61 SGPCPKDGQPSL
22 TPNIPPSFLQAM 62 PKDGQPSLVLQS
23 PPSFLQAMRKYS 63 QPSLVLQSSSFI
24 LQAMRKYSPFRN 64 VLQSSSFIFHKF
25 RKYSPFRNGYME 65 SSFIFHKFQTKA
Pool 26–30 26 PFRNGYMEPTLG Pool 66–70 66 FHKFQTKAYHPS
27 GYMEPTLGQHLP 67 QTKAYHPSFLLS
28 PTLGQHLPTLSF 68 YHPSFLLSHGLI
29 QHLPTLSFPDPG 69 FLLSHGLIQYSS
30 TLSFPDPGLRPQ 70 HGLIQYSSFHNL
Pool 31–35 31 PDPGLRPQNLYT Pool 71–75 71 QYSSFHNLHLLF
32 LRPQNLYTLWGS 72 FHNLHLLFEEYT
33 NLYTLWGSSVVC 73 HLLFEEYTNIPI
34 LWGSSVVCMYLY 74 EEYTNIPISLLF
35 SVVCMYLYQLSP 75 NIPISLLFNEKE
Pool 36–40 36 MYLYQLSPPITW Pool 76–80 76 SLLFNEKEANDT
37 QLSPPITWPLLP 77 LFNEKEANDTDH
38 SPPITWPLLPHV 78 NDTDHENGISPG
39 LLPHVIFCHPGQ 79 HENGISPGGIEP
40 VIFCHPGQLGAF 80 ISPGGIEPPSEK
Pool 81–82 81 GIEPPSEKHFRE
Control 83 GILGFVFTL 82 PPSEKHFRETEV
Peptides were diluted to obtain 10 mg/ml final concentration and pooled in groups of five. Peptide #83, located on the matrix protein of influenza A virus, was used as
control.
doi:10.1371/journal.pone.0006050.t002
STLV-1 and the Immune Response
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+ and CD8
+
T cells in tacrolimus-treated monkeys. Most importantly, in the
animal with the highest proviral load, an increased STLV-1
proviral load was observed after the immunosuppression period.
In the same animal, the increase in proviral load correlated with
increased numbers of activation and proliferation markers of
CD4
+ T cells and specifically with increased numbers of the
activation marker HLADR
+ in CD8
+ T cells. This observation
confirms the implication of T-cell expansion in viral replication
and in the expansion of infected cells after immunosuppression.
One limitation of this part of our study is the small number of
animals in the two groups undergoing immunosuppression. More
significant effects might be found in larger numbers of animals
with higher proviral loads and more aggressive immunosuppres-
sion, which could lead to the development of HTLV-1-associated
diseases such as ATLL. We are now focusing our efforts in this
direction. For example, it has been reported that treatment with
cyclophosphamide negatively affects the number of Treg cells but
totally conserves the other Th1 repertory cells [51]. Thus, to
evaluate the role of Treg cells in HTLV-1 pathogenesis, we shall
investigate the effect of cyclophosphamide in STLV-1 infected
monkeys.
In summary, we have demonstrated that naturally STLV-1-
infected mandrills could be a suitable model for studying the
relation between host and virus. Further studies are needed to
determine whether the different compartments of the immune
response during infection are responsible for the long latency, by
controlling viral replication over time. Such studies would provide




We studied 142 semi-free-ranging mandrills housed in the
Primatology Centre of the CIRMF, Gabon. Mandrills were
Figure 4. Frequency of specific IFNc-secreting T cells in six naturally STLV-infected mandrills. PBMC were cultured in the presence of 17
different pools (containing five peptides) at 10 mmol/ml, overlapping the entire Tax gene of STLVmnd (see Table 2). IFNc-releasing cells were
evaluated with the ELISPOT assay. Background levels were measured in wells containing irrelevant peptides or medium only. The frequency of
responding cells is presented after subtraction of background spots obtained with medium alone. Each bar represents the mean number of IFNc
spots in triplicate wells per million PBMC.
doi:10.1371/journal.pone.0006050.g004
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CIRMF as well as in accordance with the United States National
Institutes of Health (NIH) guidelines for the Care and Use of
Laboratory Animals. All the animal protocols and procedures
were approved by the Ethical Committee of Ile de France for
animal experimentation and by the Gabonese ethics committee for
animal experimentation, and registered under No. 08-006. The
primate centre has three veterinarians specialized in primates—an
ethologist, a primatologist, and an ecologist—and all experiments
were conducted under their supervision. Between November 2006
and January 2007, blood samples were collected from mandrills in
EDTA-K2 tubes under ketamine-HCl (10 mg/kg body weight)
anesthesia. For other immunovirological and immunosuppression
studies (see below), six STLV-1-infected mandrills were selected
from the free-ranging colony on the basis of their STLV-1 proviral
load, two monkeys having a high load, two medium and two low.
They were also selected on the basis of their ability to live together
in an isolated enclosure without aggressive behavior and without
disruption of the free-ranging breeding colony during the
experimentation period.
Serological screening
It has been reported previously that STLV-1 from mandrills is
highly homologous to human HTLV-1 subtype B (see introduc-
tion). Thus, we used the criteria for diagnosis of HTLV-1 infection
in humans to evaluate the presence of STLV-1 in our mandrill
colony [11,19].
Plasma was screened for antibodies to HTLV-I/II/STLV-1
with two enzyme-linked immunosorbent assays (ELISAs), namely
HTLV-I Platelia New (Biorad, Marnes-la-Coquette, France) and
Vironostica (Biomerieux, Marcy l’Etoile, France). STLV-1
infection was confirmed by western blotting (HTLV blot 2.4,
Diagnostic Biotechnology Ltd, Singapore). Mandrills were con-
sidered STLV-1 positive when a complete western blot profile was
obtained.
Immunosuppression
Immunosuppression was induced in mandrills by administering
tacrolimus (PrografH, 5 mg/ml, Astellas Ireland, Cokerry, Ireland)
via an intraperitoneally implanted osmotic pump (AlzetH Model
2ML4, Charles River Laboratories, l’Arbresle, France) at a dose of
Figure 5. Pharmacokinetics and virological data before (pre), during (treat) and after (post) immunusuppressive therapy. (A)
Pharmacokinetics of tacrolimus in blood over 5 weeks in three STLV-1-infected mandrills. The grey zone indicates the effective therapeutic dose in
humans. Immunological and virological data were analysed at different phases of the experiment: pretreatment corresponds to weeks –2, –1, and 0
(pre); treatment corresponds to weeks 1, 2, and 3 (treat); post-treatment corresponds to weeks 4, 5, 6, 7, and 8 (post). (B) Kinetics of STLV proviral load
during immunusuppressive therapy. Each value represents the mean6SD of measurements in triplicate for the three phases of the experiment. (C)
Kinetics of STLV proviral load in the three control animals.
doi:10.1371/journal.pone.0006050.g005
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received tacrolimus, and the other three received phosphate-
buffered saline, pH 7.2 (Biomerieux, Marcy l’Etoile, France).
Blood samples were collected at weeks –3, –2, –1, 0, +1, +2, +3,
+4, +5, +6, +7, and +8.
Before immunosuppression of the infected monkeys, the
baseline numbers of T-cell subsets (see below) were evaluated for
each animal (Table S1). The monkeys were healthy, and there was
no significant difference in the T-cell subsets of these STLV-1-
infected monkeys and those of 59 uninfected animals (Table S1).
Pharmacokinetics of tacrolimus
Tacrolimus concentrations were determined with Pro-Trac II
Tacrolimus ELISA kits, as recommended by the manufacturer
(DiaSorin, Stillwater, Minnesota, USA), in whole blood, before
treatment and weekly for 6 weeks during treatment. Tacrolimus
Figure 6. Effect of tacrolimus on T-cell subsets as measured before (pre), during (treat) and after treatment (post). Dark-grey bars
represent mean values6SD for the three mandrills treated with tacrolimus. Means6SD for the three control mandrills are shown as pale-grey bars. (A)
Percentages of CD4
+ T cells. (B) Percentages of CD8
+ T cells. (C) Expression of HLA-DR in CD4
+ T cells and (D) in CD8
+ T cells. (E) Expression of Ki67 in
CD4
+ T cells and (F) in CD8
+ T cells. *, p,0.01 as determined with the Mann-Whitney U test.
doi:10.1371/journal.pone.0006050.g006
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curve.
Flow cytometric analysis of cell-surface and intracellular
marker expression
Whole-blood samples were analyzed by four-color flow
cytometry with a standard procedure and a panel of monoclonal
antibodies (mAbs). The mAbs were originally designed to detect
human molecules but cross-react with the mandrill counterparts.
The mAbs were against CD4-fluorescein isothiocyanate (FITC)
(clone MT4-77), CD4-phycoerythrin (PE) (clone L200), CD3-
allophycocyanin (clone SP34-2), CD8-peridine chlorophyll protein
(clone SK1), HLA DR-PE (clone G46-6), CD25-PE (clone 2A3),
Ki67-FITC (clone B56), CD28-PE (clone L293), and CD95-FITC
(clone DX2), all obtained from BD Bioscience (Le Pont de Claix,
France). At least 10 000 events were acquired in the lymphocyte
square on a FACScalibur flow cytometer driven by the CellQuest
software package (Becton Dickinson, Heidelberg, Germany). Data
were analyzed with FlowJo software v7.2 (Tree Star, Inc., Ashland,
Oregon, USA).
STLV proviral load
PBMCs were separated by Ficoll density gradient centrifugation.
PBMC DNA was extracted by the phenol/chloroform procedure.
STLV proviral load was quantified by using a real-time SYBR Green
PCR method with IQ SYBR Green Supermix (Biorad, Marnes-la-
Coquette, France) on an iCycler Thermal Cycler coupled with the
iQ5 Optical System (Biorad, Marnes-la-Coquette, France). The
primer sets SK43 (CGGATACCCAGTCTACGTGT) and SK44
(GAGCCGATAACGCGTCCATCG), at a final concentration of
1.5 mmol/l,wereused to amplify a 159-base-pairfragment of the Tax
gene (location, SK43:2–22; SK44:141–161). The reaction proceeded
as follows: 5 min at 95uC, 50 cycles of 10 s at 95uC, 5 s at 60uC, and
10 s at 72uC. Melting-curve analysis was performed in 0.5uC
increments from 60uCt o9 5 uC. A standard curve was generated with
10-fold serial dilutions of MT4 cells, each of which is known to
contain seven copies of proviral HTLV. To standardize the cell
number, the albumin gene was also quantified by TaqMan PCR with
iTaq Supermix and ROX (Biorad, Marnes-la-Coquette, France).
The TaqMan probe ALBT (59FAM-CCTGTCATGCCCACA-
CAAATCTCTCC-TAMRA39)a n dt h ep r i m e r sA L B F
(GCTGTCATCTCTTGTGGGCTGT) and ALBR (ACT-
CATGGGAGCTGCTGGTTC) were used as described elsewhere
(Gabet et al., 2003). The PCR protocol consisted of 3 min at 95uC,
50cyclesfor10 sat 95uC, and 45 s at 60uC. The STLV proviral load
is reported as the copy number per 100 cells.
Enzyme-linked immunospot (ELISPOT) assay for IFN-c
We used 82 overlapping peptides covering the entire Tax
protein [52], which were divided into 17 pools, each containing
five overlapping peptides of 12 amino acids (Table 2). The
peptides were modified according to the Tax sequences obtained
from an STLV-1 infected mandrill (GenBank Accession
no. FJ755931). The peptides were diluted to 1 mg/ml in distilled
water.
The ELISPOT assay was carried out as previously described
[53]. Briefly, Multiscreen filtration plates (MAIPS4510, Millipore,
Bedford, Massachusetts, USA) were coated with 15 mg/ml of an
mAb against IFN-c (1-D1K, Mabtech, Sweden) overnight at 4uC.
The plates were then washed five times with RPMI-1640 medium
and blocked with RPMI 1640 supplemented with L-glu, pen/
strep, and 10% fetal calf serum for 2 h. Then, 2610
5 PBMC in the
above medium were added in a total volume of 200 ml, in the
presence or absence of 10 mg/ml of relevant peptide, and
incubated for 40 h at 37uC. The cells were then incubated with
100 mlo f1 mg/ml biotinylated mAb 7-B6-1 against IFNc
(Mabtech, Sweden) for 3 h at room temperature. After washing,
the substrate BCIP/NBT (Kirkegaard and Perry Labs, Gaithers-
burg, Maryland, USA) was added, and the solution was incubated
in the dark for 10–20 min until the appearance of dark-blue spots.
The reaction was stopped by washing with cold tap-water, and the
spots were counted with an Immunospot Image Analyzer (Zeiss,
Oberkochen, Germany). The frequency of responding cells,
obtained after subtracting background spots in negative control
wells (medium alone), was expressed as spot-forming cells per
million PBMC.
Statistical analysis
The Mann-Whitney U test was used to compare groups.
Correlations were sought by using the standard Pearson
correlation coefficient or Spearman’s rank correlation test.
Significance was assumed at p,0.05. All analyses were performed
with Statistica software v7.1. (StatSoft France, www.statsoft.fr).
Supporting Information
Table S1 Virological and immunological baseline values for the
six STLV-1 infected mandrills included in the Elispot assay and in
the immunosuppression treatment and for 59 uninfected animals.
Found at: doi:10.1371/journal.pone.0006050.s001 (0.05 MB
RTF)
Figure S1 Correlation between age and numbers of CD4+ and
CD8+ T cells in STLV-infected and uninfected mandrills. (A)
Absolute numbers of CD4+ T cells (cells/ml). (B) Absolute numbers
of CD8+ T cells (cells/ml). Regression curves are shown as
unbroken lines for STLV-infected mandrills and as dotted lines for
uninfected mandrills.
Found at: doi:10.1371/journal.pone.0006050.s002 (0.06 MB TIF)
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